ID   LN229/ectodomain-PODXL
AC   CVCL_D2TV
RX   PubMed=28384052;
RX   PubMed=33088928;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 9171; PODXL (ectodomain).
CC   Derived from site: In situ; Brain, right frontal parieto-occipital cortex.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0393 ! LN-229
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 30-01-24; Version: 1
//
RX   PubMed=28384052; DOI=10.1089/mab.2017.0008;
RA   Ogasawara S., Kaneko M.K., Yamada S., Honma R., Nakamura T.,
RA   Saidoh N., Yanaka M., Yoshida K., Fujii Y., Kato Y.;
RT   "PcMab-47: novel antihuman podocalyxin monoclonal antibody for
RT   immunohistochemistry.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 36:50-56(2017).
//
RX   PubMed=33088928; DOI=10.1016/j.bbrep.2020.100826;
RA   Kaneko M.K., Ohishi T., Kawada M., Kato Y.;
RT   "A cancer-specific anti-podocalyxin monoclonal antibody (60-mG(2a)-f)
RT   exerts antitumor effects in mouse xenograft models of pancreatic
RT   carcinoma.";
RL   Biochem. Biophys. Rep. 24:100826.1-100826.7(2020).
//